KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Amortizatization of Intangibles (2016 - 2025)

Sarepta Therapeutics (SRPT) has 9 years of Amortizatization of Intangibles data on record, last reported at -$380000.0 in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 94.41% year-over-year to -$380000.0; the TTM value through Dec 2025 reached -$5.3 million, up 86.86%, while the annual FY2025 figure was -$5.3 million, 86.86% up from the prior year.
  • Amortizatization of Intangibles reached -$380000.0 in Q4 2025 per SRPT's latest filing, up from -$1.1 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at -$50000.0 in Q1 2022 and bottomed at -$13.3 million in Q4 2023.
  • Average Amortizatization of Intangibles over 4 years is -$6.4 million, with a median of -$6.5 million recorded in 2022.
  • Peak YoY movement for Amortizatization of Intangibles: plummeted 17202.0% in 2023, then skyrocketed 94.41% in 2025.
  • A 4-year view of Amortizatization of Intangibles shows it stood at -$6.1 million in 2022, then plummeted by 117.33% to -$13.3 million in 2023, then skyrocketed by 48.96% to -$6.8 million in 2024, then surged by 94.41% to -$380000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were -$380000.0 in Q4 2025, -$1.1 million in Q3 2025, and -$1.9 million in Q2 2025.